| E-Folder |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Team Building > Team Meeting or Team Building? The Choice is Yours |
|
E-Folder - Team Meeting or Team Building? The Choice is Yours
Ask most leaders to describe team building or team development and they will immediately talk of offsites or 'away-days', paintballing, high-ropes exercises and orienteering. All fantastic in their own rights, but forget them for a moment and consider this: used in the right wa According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product y, the plain old team meeting is one of the most effective, easily-organised and least costly tools for team building and development. I recently spoke to a sales manager preparing to go to a team meeting offsite, and he was not looking forward to it! When I asked him why he ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in old me that whilst these meetings are always good fun, they have some serious failings:
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. whole meeting is spent looking forward towards long-term, high-level goals and the team never refers back to what was agreed last time or to consider the lessons that can be learned from what has happened since the last meeting here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe riend resented the work he was putting into his presentation on projected sales because he felt that, after the team meeting, he would never again be asked whether he had achieved it, where he had had success or indeed where he had failed.
I was interested - my experie d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro ce of team meetings has often been quite different. When I ask the teams I work with what works well and what hinders them, some common complaints appear time and time again:
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc impression that the team meeting, and maybe even the team, is well down the leaders' priority list easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi people regularly leave the room to take or make 'important' calls. All of these issues are symptomatic of a lack of interest in the meeting, probably due to a perceived lack of value in the meeting nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ad from the team leader, followed by an update from each team member about what they are currently working on - team members often find this more of an exercise in proving that they are working rather than adding any value in helping them to achieve their goals and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ten little attention given to communal problem-solving or ensuring individual activities continue to fit with the team's overall purpose - exercises that would add value, build mutual accountability and utilise team strengths to best advantage.
Team meetings don't have ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi to be like this. Structure your team meetings well and you will see the difference in your team members' motivation and commitment through their attendance - always a good start! - and contribution to the team meeting. High performing teams employ some common practices for their te ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a am meetings:
dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod d participation
cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin prepare
tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ically is the team going to deliver between this meeting and the next one?
t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel tings as a form of self-assessment for the team
ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust plaud the successes since last meeting y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ne member
I will leave you with a quote, the spirit of which I . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de think many of us will recognise: "[If] we are all in agreement on the decision . . . then I propose we postpone further discussion of this matter until our next meeting to give ourselves time to develop disagreement and perhaps gain some understanding of what the decision is elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ll about." - Alfred P. Sloan, Jr. (1875 - 1966), a US auto executive Don't let this be you! It is still early enough in the year to make another resolution, so make a commitment to implement the 7 simple steps above, and keep it! © Allagi Consulting 2007. All rights reserved tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Some Things I've Learned Since Losing My Job How to Establish your Self Confidence as an Entrepreneur Small Business Video Surveillance
|